Stage migration in localized prostate cancer has no effect on the post‐radical prostatectomy Kattan nomogram

Study Type – Prognosis (case series)
Level of Evidence 4 OBJECTIVE To investigate the effect of prostate‐specific antigen (PSA) testing on stage migration in an Australian population, and its consequences on the prognostic accuracy of the post‐radical prostatectomy (RP) Kattan nomogram, as in North...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2010-03, Vol.105 (5), p.642-647
Main Authors: Thanigasalam, Ruban, Rasiah, Krishan K., Stricker, Phillip D., Haynes, Anne Maree, Sutherland, Sarah I.M., Sutherland, Robert L., Henshall, Susan M., Horvath, Lisa G.
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Epidemiologic Methods
Gynecology. Andrology. Obstetrics
Humans
Lymphatic Metastasis
Male
Male genital diseases
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - pathology
Nephrology. Urinary tract diseases
nomogram
Nomograms
Prognosis
prostate cancer
Prostatectomy - methods
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
stage migration
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study Type – Prognosis (case series)
Level of Evidence 4 OBJECTIVE To investigate the effect of prostate‐specific antigen (PSA) testing on stage migration in an Australian population, and its consequences on the prognostic accuracy of the post‐radical prostatectomy (RP) Kattan nomogram, as in North America widespread PSA testing has resulted in prostate cancer stage migration, questioning the utility of prognostic nomograms in this setting. PATIENTS AND METHODS The study comprised 1008 men who had consecutive RP for localized prostate cancer between 1991 and 2001 at one institution. Two groups were assessed, i.e. those treated in 1991–96 (group 1, the early PSA era), and 1997–2001 (group 2, the contemporary PSA era). Differences in clinicopathological features between the groups were analysed by chi‐squared testing and survival modelling. Individual patient data were entered into the post‐RP Kattan nomogram and the efficacy assessed by receiver‐ operating characteristic curve analysis. RESULTS Patients in group 2 had lower pathological stage disease (P = 0.01) and fewer cancers with Gleason score ≥8 (P 
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2009.08842.x